- Home
- BGR vs ALT Comparison
BGR vs ALT Comparison
Compare BGR & ALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BGR | ALT |
|---|---|---|
| Founded | 2004 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 417.0M | 421.5M |
| IPO Year | N/A | 2005 |
Fundamental Metrics
Financial Performance| Metric | BGR | ALT |
|---|---|---|
| Price | $14.65 | $2.81 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $17.67 |
| AVG Volume (30 Days) | 117.8K | ★ 3.4M |
| Earning Date | 01-01-0001 | 05-08-2026 |
| Dividend Yield | ★ 6.02% | N/A |
| EPS Growth | N/A | ★ 25.37 |
| EPS | ★ 0.69 | N/A |
| Revenue | N/A | ★ $41,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $21.46 | ★ N/A |
| Revenue Growth | N/A | ★ 105.00 |
| 52 Week Low | $12.92 | $2.56 |
| 52 Week High | $17.70 | $6.44 |
Technical Indicators
Market Signals| Indicator | BGR | ALT |
|---|---|---|
| Relative Strength Index (RSI) | 34.68 | 48.08 |
| Support Level | $14.51 | $2.72 |
| Resistance Level | $16.26 | $3.20 |
| Average True Range (ATR) | 0.32 | 0.12 |
| MACD | -0.07 | 0.03 |
| Stochastic Oscillator | 9.94 | 49.45 |
Price Performance
Historical ComparisonAbout BGR BlackRock Energy and Resources Trust
BlackRock Energy & Resources Trust is a closed-end equity fund providing total return through a combination of current income, gains, and capital appreciation by investing in equity securities and derivatives of energy and natural resources companies. The fund invests in various sectors such as information technology, financials, healthcare, consumer discretionary, industrial, energy, materials, utilities, and others.
About ALT Altimmune Inc.
Altimmune Inc is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company's key candidate, pemvidutide, is a dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.